Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy
© The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissionsoup.com..
Long-term treatment with interferon (IFN) alfa plus ribavirin decreases the proviral human immunodeficiency virus type 1 (HIV) DNA level. However, the short-term impact of IFN alfa on persistent HIV and its effects on immune activation after antiretroviral therapy remain unknown. Our study showed that the cell-associated HIV RNA level and CD4(+) T-cell activation decreased in the IFN group (n = 10). No changes were detected in levels of residual plasma viremia, replication-competent reservoirs, proviral DNA, or 2-long-terminal repeat circles, although APOBEC3G, TRIM5α, BST2, and TRIM22 were upregulated in the IFN group. These data suggest that short-term treatment with IFN alfa combined with RBV decreases HIV expression, in part through inhibition of HIV transcription by TRIM22 and decrease in T-cell activation.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:213 |
|---|---|
| Enthalten in: |
The Journal of infectious diseases - 213(2016), 6 vom: 15. März, Seite 1008-12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Morón-López, Sara [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.07.2016 Date Revised 16.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1093/infdis/jiv521 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM25424890X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM25424890X | ||
| 003 | DE-627 | ||
| 005 | 20231224171952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/infdis/jiv521 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0847.xml |
| 035 | |a (DE-627)NLM25424890X | ||
| 035 | |a (NLM)26525407 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Morón-López, Sara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral Therapy |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.07.2016 | ||
| 500 | |a Date Revised 16.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author 2015. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissionsoup.com. | ||
| 520 | |a Long-term treatment with interferon (IFN) alfa plus ribavirin decreases the proviral human immunodeficiency virus type 1 (HIV) DNA level. However, the short-term impact of IFN alfa on persistent HIV and its effects on immune activation after antiretroviral therapy remain unknown. Our study showed that the cell-associated HIV RNA level and CD4(+) T-cell activation decreased in the IFN group (n = 10). No changes were detected in levels of residual plasma viremia, replication-competent reservoirs, proviral DNA, or 2-long-terminal repeat circles, although APOBEC3G, TRIM5α, BST2, and TRIM22 were upregulated in the IFN group. These data suggest that short-term treatment with IFN alfa combined with RBV decreases HIV expression, in part through inhibition of HIV transcription by TRIM22 and decrease in T-cell activation | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CD4+ T-cell subpopulations | |
| 650 | 4 | |a HIV RNA expression | |
| 650 | 4 | |a HIV persistence | |
| 650 | 4 | |a HIV/HCV coinfection | |
| 650 | 4 | |a IFN alfa | |
| 650 | 4 | |a Siglec-1 | |
| 650 | 4 | |a TRIM22 | |
| 650 | 4 | |a immune activation | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Interferon-alpha |2 NLM | |
| 650 | 7 | |a Recombinant Proteins |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 650 | 7 | |a Ribavirin |2 NLM | |
| 650 | 7 | |a 49717AWG6K |2 NLM | |
| 650 | 7 | |a peginterferon alfa-2a |2 NLM | |
| 650 | 7 | |a Q46947FE7K |2 NLM | |
| 700 | 1 | |a Gómez-Mora, Elisabet |e verfasserin |4 aut | |
| 700 | 1 | |a Salgado, Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Ouchi, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Puertas, Maria C |e verfasserin |4 aut | |
| 700 | 1 | |a Urrea, Víctor |e verfasserin |4 aut | |
| 700 | 1 | |a Navarro, Jordi |e verfasserin |4 aut | |
| 700 | 1 | |a Jou, Antoni |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez, Mercedes |e verfasserin |4 aut | |
| 700 | 1 | |a Tural, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Clotet, Bonaventura |e verfasserin |4 aut | |
| 700 | 1 | |a Montaner, Luis J |e verfasserin |4 aut | |
| 700 | 1 | |a Blanco, Julià |e verfasserin |4 aut | |
| 700 | 1 | |a Crespo, Manuel |e verfasserin |4 aut | |
| 700 | 1 | |a Martinez-Picado, Javier |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The Journal of infectious diseases |d 1945 |g 213(2016), 6 vom: 15. März, Seite 1008-12 |w (DE-627)NLM000005819 |x 1537-6613 |7 nnns |
| 773 | 1 | 8 | |g volume:213 |g year:2016 |g number:6 |g day:15 |g month:03 |g pages:1008-12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/infdis/jiv521 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 213 |j 2016 |e 6 |b 15 |c 03 |h 1008-12 | ||